

## Coming Soon:

# illumina Infinium Global Screening Array v3.0 (GSA) testing

### What is the GSAv3.0 Array?

Clinical Enterprise Inc. is now offering up to date genetic analysis using the Infinium Global Screening Array (GSA) v3.0 run on the Illumina iScan Platform. The GSA assesses >650,000 genetic markers related to a broad range clinical and research applications including polygenic risk scoring for cardiovascular disease, colon cancer, breast cancer, prostate cancer, diabetes, and dementia. Other applications include pharmacogenetics and ethnic diversity.

### What we provide:

- **Quality testing:** Clinical Enterprise (CE) is a subsidiary of Eurofins Scientific, a global leader in laboratory testing services. Samples are processed in our new CLIA/CAP certified high-throughput laboratory in Framingham, MA.
- **Fast Turnaround:** After sample receipt, results can be expected in less than 7 days
- **Flexible reporting:**
  - Genotyping reports in excel or other text-based format
  - Raw data files from the iScan for flexible downstream analysis such as Genome-wide Association Studies (GWAS) or other academic research
- **Quality control:** Upon request, quality parameters such as call rate can be provided for individual samples

### What types of specimens are acceptable?

- Buccal swab collected using a standard flocked swab shipped dry overnight (ex. 4N6FLOQSwabs cat# 4473979)
- Saliva sample collected with a standard saliva collection device with preservative. Examples include the Omnigene OME-505, GeneFix GFX-02, or Oragene DNA 0G-600.

### Future Offerings

- Polygenic risk scores (PRS) for cardiovascular disease, breast, prostate, and colon cancer, dementia, and diabetes.
- Add-on genetic markers for any non-standard array content
- Validation and launch of the Global Diversity Array (GDA) which offers genotyping data on >1.8 Million genetic markers.